文献速递临床试验与 GCP

异氟烷吸入镇静用于急性低氧性呼吸衰竭机械通气成人:SAVE-ICU随机临床试验

Isoflurane-Based Inhaled Sedation in Mechanically Ventilated Adults With Acute Hypoxemic Respiratory Failure: The SAVE-ICU Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-10-14

SAVE-ICU是一项在加拿大14个ICU开展的实用、开放标签、优效性随机临床试验,纳入786例急性低氧性呼吸衰竭机械通气成人,比较异氟烷吸入镇静策略与常规静脉镇静策略。主要结局显示两组院内死亡率无显著差异(42.5% vs 43.8%;RR 0.98,95%CI 0.84-1.14;

要点

  • 异氟烷吸入镇静未降低急性低氧性呼吸衰竭机械通气患者的院内死亡率。
  • 吸入镇静组接受更多难治性低氧血症辅助治疗(63.9% vs 55.0%)。
  • 吸入镇静组谵妄和昏迷无天数更少(组间差-0.95,95%CI -1.69至-0.22)。

核心结论

  • 在急性低氧性呼吸衰竭机械通气成人中,异氟烷吸入镇静策略联合按需静脉辅助镇静与静脉镇静策略相比未降低院内死亡率。

研究设计与样本

  • 实用、实效性、开放标签、优效性随机临床试验,在加拿大14个ICU开展。
  • 纳入786例成人(≥18岁),镇静时间小于72小时且因非COVID或COVID-19呼吸衰竭机械通气,PaO2:FIO2小于300 mm Hg。
  • 780例纳入主要分析,异氟烷吸入镇静组385例,静脉镇静组395例;平均年龄61.1岁,女性34.0%,非COVID AHRF占73.7%,平均PaO2:FIO2为152.6 mm Hg。

主要发现

  • 预设亚组分析(年龄、性别、COVID-19状态)未见效应修饰。
  • ICU无天数、无呼吸机天数和无住院天数两组相似。
  • 吸入镇静组接受更多低氧血症辅助治疗:63.9%(239例)vs 55.0%(214例),组间差8.89%(95%CI 1.95%-15.83%)。
  • 吸入镇静组第14天谵妄和昏迷无天数更少:组间差-0.95(95%CI -1.69至-0.22);3个月生活质量和残疾评分两组无差异。

临床怎么用

  • 对于急性低氧性呼吸衰竭机械通气成人,异氟烷吸入镇静策略不能作为降低院内死亡率的常规推荐。
  • 临床考虑使用异氟烷吸入镇静时需注意其可能增加低氧血症辅助治疗需求并减少谵妄和昏迷无天数。

局限性

  • 开放标签设计可能影响临床决策。
  • 吸入镇静组中49.9%至55.4%的患者在随机化后前14天内同时接受静脉镇静。
  • 研究在加拿大14个ICU开展,外推性需谨慎评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Rigorous evidence for inhaled sedation using isoflurane in mechanically ventilated patients with acute hypoxemic respiratory failure (AHRF) is limited. OBJECTIVE: To evaluate whether an inhaled sedation strategy lowers hospital mortality compared with usual care intravenous sedation strategy in mechanically ventilated adults with AHRF. DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, effectiveness, open-label, superiority, randomized clinical trial in 14 intensive care units (ICUs) in Canada. Adults (≥18 years) receiving sedation for less than 72 hours and receiving mechanical ventilation for AHRF from non-COVID respiratory failure (ratio of partial pressure of arterial oxygen [Pao2] to fraction of inspired oxygen [Fio2] <300 mm Hg) or COVID-19 were enrolled between September 2020 and March 2025 with follow-up through June 2025. INTERVENTION: Patients were randomized to an inhaled sedation strategy using isoflurane with intravenous adjuncts as clinically needed or to a usual intravenous sedation care strategy. Sedatives were titrated to achieve the desired target sedation score guided by clinical teams and continued until extubation or death. MAIN OUTCOMES AND MEASURES: Primary outcome was all-cause hospital mortality. Secondary outcomes included ICU- and ventilator-free days at day 30; hospital-free days at day 60; use of refractory hypoxemia adjunctive therapies; delirium- and coma-free days at day 14; and quality-of-life and disability scores at 3 months. RESULTS: Of 786 patients randomized, 780 were included in the primary analysis (mean age, 61.1 years; 34.0% female; 73.7% non-COVID AHRF, mean Pao2:Fio2 ratio, 152.6 mm Hg); 385 in the inhaled sedation and 395 in the intravenous sedation groups. In the inhaled sedation group, 49.9% to 55.4% of patients received concomitant intravenous sedation on any day during the first 14 days after randomization. At hospital discharge, 161 of 379 patients (42.5%) in the inhaled sedation group had died, compared with 171 of 390 patients (43.8%) in the intravenous sedation group (risk ratio, 0.98 [95% CI, 0.84 to 1.14]; P = .85). There was no effect modification in prespecified subgroup analyses for age, sex, and COVID-19 status. ICU-, ventilator-, and hospital-free days were similar between groups. The inhaled sedation group received more adjunctive therapies for hypoxemia (239 [63.9%] vs 214 [55.0%]; between-group difference, 8.89% [95% CI, 1.95% to 15.83%]) and had fewer delirium- and coma-free days (between-group difference, -0.95 [95% CI, -1.69 to -0.22]). There was no difference in quality-of-life and disability scores between groups. CONCLUSIONS AND RELEVANCE: In mechanically ventilated adults with AHRF, an inhaled sedation strategy using isoflurane with intravenous adjuncts as clinically needed did not reduce hospital mortality compared with an intravenous sedation strategy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04415060.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Jerath A, Slessarev M, Martin C, et al. Isoflurane-Based Inhaled Sedation in Mechanically Ventilated Adults With Acute Hypoxemic Respiratory Failure: The SAVE-ICU Randomized Clinical Trial. JAMA. 2026. PMID: 42872958. doi:10.1001/jama.2026.18471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。